Reneo Pharmaceuticals Stock Forecast, Price & News

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Reneo Pharmaceuticals in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Reneo Pharmaceuticals stock.
View analyst ratings for Reneo Pharmaceuticals or view top-rated stocks.

Wall Street analysts have given Reneo Pharmaceuticals a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Reneo Pharmaceuticals wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

3 brokers have issued 12-month price targets for Reneo Pharmaceuticals' stock. Their forecasts range from $24.00 to $45.00. On average, they anticipate Reneo Pharmaceuticals' stock price to reach $31.33 in the next year. This suggests a possible upside of 181.0% from the stock's current price.
View analysts' price targets for Reneo Pharmaceuticals or view top-rated stocks among Wall Street analysts.

Some companies that are related to Reneo Pharmaceuticals include PureTech Health (PRTC), Kinnate Biopharma (KNTE), Silverback Therapeutics (SBTX), Connect Biopharma (CNTB), Stem (STEM), Oxford Biomedica (OXB), Pharming Group (PHAR), iTeos Therapeutics (ITOS), Vor Biopharma (VOR), Gracell Biotechnologies (GRCL), 4D Molecular Therapeutics (FDMT), Pharvaris B.V. (PHVS), Bolt Biotherapeutics (BOLT), 22nd Century Group (XXII) and Ergomed (ERGO).
View all of RPHM's competitors.

(RPHM) raised $101 million in an initial public offering on Friday, April 9th 2021. The company issued 6,300,000 shares at $15.00-$17.00 per share. Jefferies, SVB Leerink and Piper Sandler served as the underwriters for the IPO.

Reneo Pharmaceuticals trades on the NASDAQ under the ticker symbol "RPHM."

Reneo Pharmaceuticals' quiet period expires on Wednesday, May 19th. Reneo Pharmaceuticals had issued 6,250,000 shares in its public offering on April 9th. The total size of the offering was $93,750,000 based on an initial share price of $15.00. During the company's quiet period, insiders and underwriters involved in the IPO are restricted from issuing any research reports for the company because of SEC regulations. Following the expiration of the company's quiet period, it's expected that the brokerages that served as underwriters on the stock will initiate research coverage on the company.

Shares of RPHM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of RPHM stock can currently be purchased for approximately $11.15.

Reneo Pharmaceuticals has a market capitalization of $269.95 million.

Reneo Pharmaceuticals employs 12 workers across the globe.

The official website for Reneo Pharmaceuticals is reneopharma.com.

The company can be reached via phone at 858-283-0280.